Gossamer’s seralutinib is designed to treat pulmonary arterial hypertension and other indications
Chiesi Group and Gossamer Bio have announced a global collaboration and license agreement to develop and commercialise seralutinib to treat respiratory diseases.
Chiesi will support Gossamer’s ongoing work for seralutinib in pulmonary arterial hypertension (PAH), as well as its development in pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Predicted to affect up to 50,000 people in the US, PAH is a rare, progressive condition that causes high blood pressure in the lungs’ arteries. It is estimated that PH-ILD affects up to 100,000 patients in the US.
Seralutinib is an inhaled inhibitor designed to be delivered via a dry powder inhaler for the potential treatment of pulmonary hypertension.
As part of the deal, Chiesi will pay Gossamer $160m as a development reimbursement and the biopharmaceutical company will also be eligible to receive up to $146m in regulatory milestones and $180m in sales milestones.
Under the terms of the agreement, Gossamer will lead the global development of seralutinib in PAH and PH-ILD, and both companies will evenly split development costs, excluding the PROSERA study.
Both companies will evenly share commercial profits and losses, contributing 50% of commercial efforts in the US, while Gossamer will lead commercialisation and book sales for PAH and PH-ILD and Chiesi will lead commercialisation in additional indications.
Additionally, Chiesi will gain exclusive rights to commercialise seralutinib outside of the US, paying Gossamer a mid-to-high teens royalty on net sales.
Faheem Hasnain, co-founder, chairman and chief executive officer, Gossamer, commented: “This collaboration enables seralutinib to move directly into a phase 3 trial in PH-ILD, an indication with a paucity of available treatments and a disease which we believe seralutinib is specifically designed to address.”
Giuseppe Accogli, group chief executive officer, Chiesi said: “Seralutinib is a potential paradigm shifting therapy in PAH and PH-ILD and we… [are] excited to partner with Gossamer to develop and bring this therapy to patients worldwide.”
0
0
